Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (1349) Stock Overview
Engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
1349 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.26 |
| 52 Week High | HK$5.29 |
| 52 Week Low | HK$2.20 |
| Beta | 0.090 |
| 1 Month Change | -5.04% |
| 3 Month Change | -21.53% |
| 1 Year Change | -27.33% |
| 3 Year Change | -12.74% |
| 5 Year Change | -55.34% |
| Change since IPO | 182.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1349 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -2.6% | -4.7% | -4.7% |
| 1Y | -27.3% | -18.1% | -4.2% |
Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: 1349 underperformed the Hong Kong Market which returned -4.2% over the past year.
Price Volatility
| 1349 volatility | |
|---|---|
| 1349 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.3% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 1349 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1349's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 876 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1349 fundamental statistics | |
|---|---|
| Market cap | HK$6.41b |
| Earnings (TTM) | -HK$175.79m |
| Revenue (TTM) | HK$755.51m |
Is 1349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1349 income statement (TTM) | |
|---|---|
| Revenue | CN¥654.94m |
| Cost of Revenue | CN¥67.06m |
| Gross Profit | CN¥587.88m |
| Other Expenses | CN¥740.27m |
| Earnings | -CN¥152.39m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 89.76% |
| Net Profit Margin | -23.27% |
| Debt/Equity Ratio | 0% |
How did 1349 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 03:02 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Hu | Deutsche Bank |
| Feng Qiang Sun | Guotai Haitong/Guotai Junan International Holdings Limited |
| Xiang Jun | Industrial Securities Co. Ltd. |